A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS

NCT04071158

Last updated date
Study Location
Clinical Research Atlanta
Stockbridge, Georgia, 30281, United States
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Respiratory Tract Infection
Sex
Female
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18-49 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy women ≥18 and ≤49 years of age who are of childbearing potential or not of childbearing potential. (Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included.)

- Willing and able to comply with all scheduled visits, treatment plan, lifestyle considerations, and other study procedures.

- Expected to be available for the duration of the study and can be contacted by telephone during study participation.

- Body mass index (BMI) of <40 kg/m2 at the time of the consent.

- Capable of giving signed informed consent as which includes compliance with the requirements and restrictions listed within.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Other acute or chronic medical or psychiatric condition including recent (within the
past year) or active suicidal ideation or behavior or laboratory abnormality that may
increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results and, in the
judgment of the investigator, would make the participant inappropriate for entry into
this study.


- Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or
hepatitis B virus (HBV).


- History of severe adverse reaction associated with a vaccine and/or severe allergic
reaction (eg, anaphylaxis) to any component of the vaccines being administered in the
study.


- History of latex allergy.


- Immunocompromised participants with known or suspected immunodeficiency, as determined
by history, laboratory tests, and/or physical examination.


- Any contraindication to Tdap (including encephalopathies).


- History of autoimmune disease or an active autoimmune disease requiring therapeutic
intervention, including but not limited to systemic or cutaneous lupus erythematosus,
autoimmune arthritis/rheumatoid arthritis, Guillain-Barré syndrome, multiple
sclerosis, Sjögren's syndrome, idiopathic thrombocytopenia purpura,
glomerulonephritis, autoimmune thyroiditis, giant cell arteritis (temporal arteritis),
psoriasis, and insulin dependent diabetes mellitus (type 1).


- Bleeding diathesis or condition associated with prolonged bleeding that would, in the
opinion of the investigator, contraindicate intramuscular injection.


- Women who are pregnant or breastfeeding.


- Previous vaccination with any licensed or investigational RSV vaccine, or planned
receipt of nonstudy RSV vaccine throughout the study.


- Treatment with immunosuppressive therapy, including cytotoxic agents or systemic
corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt
throughout the study. If systemic corticosteroids have been administered short term
(<14 days) for treatment of an acute illness, participants should not be enrolled into
the study until corticosteroid therapy has been discontinued for at least 28 days
before investigational product administration. Inhaled/nebulized, intra-articular,
intrabursal, or topical (skin or eyes) corticosteroids are permitted.


- Receipt of blood/plasma products or immunoglobulin within 60 days before
investigational product administration or planned receipt throughout the study.


- Current alcohol abuse, marijuana abuse, or illicit drug use.


- Vaccination within 5 years with DTaP or tetanus and diphtheria toxoids adsorbed (Td)
vaccine before investigational product administration.


- Investigator site staff members directly involved in the conduct of the study and
their family members, site staff members otherwise supervised by the investigator, or
Pfizer employees, including their family members, directly involved in the conduct of
the study.


- Current febrile illness (oral temperature ≥38.0C [≥100.4F]) or other acute illness
within 48 hours before investigational product administration.


- Receipt of any inactivated vaccine within 14 days and any live vaccine within 28 days
before or anticipated receipt of any vaccine within the 14 days after investigational
product administration.


- Receipt of short-term (<14 days) systemic corticosteroids. Investigational product
administration should be delayed until systemic corticosteroid use has been
discontinued for at least 28 days. Inhaled/nebulized, intra-articular, intrabursal, or
topical (skin or eyes) corticosteroids do not require temporary delay of
investigational product administration.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Respiratory Tract InfectionA Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.
NCT04424316
  1. Canoas, RS
  2. Joinville, SC
  3. Santiago, Región Metropolitana
  4. Santiago, Región Metropolitana
  5. Birmingham, Alabama
  6. Birmingham, Alabama
  7. Birmingham, Alabama
  8. Birmingham, Alabama
  9. Birmingham, Alabama
  10. Birmingham, Alabama
  11. Birmingham, Alabama
  12. Birmingham, Alabama
  13. Cullman, Alabama
  14. Cullman, Alabama
  15. Cullman, Alabama
  16. Mobile, Alabama
  17. Mobile, Alabama
  18. Mobile, Alabama
  19. Phoenix, Arizona
  20. Phoenix, Arizona
  21. Phoenix, Arizona
  22. Tucson, Arizona
  23. Tucson, Arizona
  24. Tucson, Arizona
  25. Tucson, Arizona
  26. Tucson, Arizona
  27. Jonesboro, Arkansas
  28. Jonesboro, Arkansas
  29. Jonesboro, Arkansas
  30. Jonesboro, Arkansas
  31. Chowchilla, California
  32. Huntington Park, California
  33. Huntington Park, California
  34. Huntington Park, California
  35. Lancaster, California
  36. Lancaster, California
  37. Loma Linda, California
  38. Loma Linda, California
  39. Loma Linda, California
  40. Loma Linda, California
  41. Loma Linda, California
  42. Long Beach, California
  43. Long Beach, California
  44. Long Beach, California
  45. Los Angeles, California
  46. Los Angeles, California
  47. Los Angeles, California
  48. Los Angeles, California
  49. Los Angeles, California
  50. Los Angeles, California
  51. Los Angeles, California
  52. Los Angeles, California
  53. Madera, California
  54. Madera, California
  55. Madera, California
  56. Madera, California
  57. Santa Monica, California
  58. Santa Monica, California
  59. Santa Monica, California
  60. Stanford, California
  61. Aurora, Colorado
  62. Aurora, Colorado
  63. Aurora, Colorado
  64. Aurora, Colorado
  65. Aurora, Colorado
  66. Aurora, Colorado
  67. Aurora, Colorado
  68. Aurora, Colorado
  69. Delta, Colorado
  70. Fruita, Colorado
  71. Grand Junction, Colorado
  72. Grand Junction, Colorado
  73. Grand Junction, Colorado
  74. Grand Junction, Colorado
  75. Grand Junction, Colorado
  76. Montrose, Colorado
  77. Washington, District of Columbia
  78. Washington, District of Columbia
  79. Washington, District of Columbia
  80. Loxahatchee Groves, Florida
  81. Miami, Florida
  82. North Miami Beach, Florida
  83. North Miami Beach, Florida
  84. Panama City, Florida
  85. Panama City, Florida
  86. Panama City, Florida
  87. Panama City, Florida
  88. Atlanta, Georgia
  89. Atlanta, Georgia
  90. Atlanta, Georgia
  91. Atlanta, Georgia
  92. Augusta, Georgia
  93. Augusta, Georgia
  94. Columbus, Georgia
  95. Columbus, Georgia
  96. Blackfoot, Idaho
  97. Blackfoot, Idaho
  98. Blackfoot, Idaho
  99. Idaho Falls, Idaho
  100. Idaho Falls, Idaho
  101. Nampa, Idaho
  102. Nampa, Idaho
  103. Nampa, Idaho
  104. Pocatello, Idaho
  105. Pocatello, Idaho
  106. Fort Wayne, Indiana
  107. Fort Wayne, Indiana
  108. Ames, Iowa
  109. Ames, Iowa
  110. Ames, Iowa
  111. Ames, Iowa
  112. Ankeny, Iowa
  113. West Des Moines, Iowa
  114. West Des Moines, Iowa
  115. El Dorado, Kansas
  116. Kansas City, Kansas
  117. Newton, Kansas
  118. Wichita, Kansas
  119. Wichita, Kansas
  120. Owensboro, Kentucky
  121. Owensboro, Kentucky
  122. Alexandria, Louisiana
  123. Alexandria, Louisiana
  124. Covington, Louisiana
  125. Gretna, Louisiana
  126. Lafayette, Louisiana
  127. Metairie, Louisiana
  128. New Orleans, Louisiana
  129. New Orleans, Louisiana
  130. New Orleans, Louisiana
  131. New Orleans, Louisiana
  132. New Orleans, Louisiana
  133. New Orleans, Louisiana
  134. New Orleans, Louisiana
  135. New Orleans, Louisiana
  136. Slidell, Louisiana
  137. Boston, Massachusetts
  138. Boston, Massachusetts
  139. Detroit, Michigan
  140. Detroit, Michigan
  141. Detroit, Michigan
  142. Southfield, Michigan
  143. Blaine, Minnesota
  144. Coon Rapids, Minnesota
  145. Coon Rapids, Minnesota
  146. Coon Rapids, Minnesota
  147. Fridley, Minnesota
  148. Maple Grove, Minnesota
  149. Minneapolis, Minnesota
  150. Minneapolis, Minnesota
  151. Minneapolis, Minnesota
  152. Gulfport, Mississippi
  153. Saint Louis, Missouri
  154. Saint Louis, Missouri
  155. Saint Louis, Missouri
  156. Saint Louis, Missouri
  157. Butte, Montana
  158. Great Falls, Montana
  159. Helena, Montana
  160. Kalispell, Montana
  161. Missoula, Montana
  162. Grand Island, Nebraska
  163. Hastings, Nebraska
  164. Hastings, Nebraska
  165. Lincoln, Nebraska
  166. Lincoln, Nebraska
  167. Lincoln, Nebraska
  168. Norfolk, Nebraska
  169. Las Vegas, Nevada
  170. Las Vegas, Nevada
  171. Las Vegas, Nevada
  172. Camden, New Jersey
  173. Camden, New Jersey
  174. Camden, New Jersey
  175. Cherry Hill, New Jersey
  176. New Brunswick, New Jersey
  177. Newark, New Jersey
  178. Newark, New Jersey
  179. Newark, New Jersey
  180. Newark, New Jersey
  181. Sewell, New Jersey
  182. Albuquerque, New Mexico
  183. Albuquerque, New Mexico
  184. East Setauket, New York
  185. East Setauket, New York
  186. East Setauket, New York
  187. Endwell, New York
  188. Flushing, New York
  189. Flushing, New York
  190. Fresh Meadows, New York
  191. Hollis, New York
  192. Jackson Heights, New York
  193. Johnson City, New York
  194. Mineola, New York
  195. Mineola, New York
  196. Mineola, New York
  197. Mineola, New York
  198. New Hyde Park, New York
  199. New York, New York
  200. New York, New York
  201. New York, New York
  202. New York, New York
  203. New York, New York
  204. New York, New York
  205. Rochester, New York
  206. Stony Brook, New York
  207. Durham, North Carolina
  208. Durham, North Carolina
  209. Durham, North Carolina
  210. Durham, North Carolina
  211. Pinehurst, North Carolina
  212. Pinehurst, North Carolina
  213. Raleigh, North Carolina
  214. Seven Lakes, North Carolina
  215. Southern Pines, North Carolina
  216. Southern Pines, North Carolina
  217. Dayton, Ohio
  218. Englewood, Ohio
  219. Yukon, Oklahoma
  220. Erie, Pennsylvania
  221. Erie, Pennsylvania
  222. Erie, Pennsylvania
  223. Erie, Pennsylvania
  224. Hershey, Pennsylvania
  225. Hershey, Pennsylvania
  226. Philadelphia, Pennsylvania
  227. Philadelphia, Pennsylvania
  228. West Reading, Pennsylvania
  229. West Reading, Pennsylvania
  230. West Reading, Pennsylvania
  231. Charleston, South Carolina
  232. Charleston, South Carolina
  233. Greenville, South Carolina
  234. Greenville, South Carolina
  235. Greenville, South Carolina
  236. Summerville, South Carolina
  237. Summerville, South Carolina
  238. Clarksville, Tennessee
  239. Knoxville, Tennessee
  240. Arlington, Texas
  241. Austin, Texas
  242. Beaumont, Texas
  243. Beaumont, Texas
  244. Beaumont, Texas
  245. Beaumont, Texas
  246. Burleson, Texas
  247. Dallas, Texas
  248. Dickinson, Texas
  249. Fort Worth, Texas
  250. Fort Worth, Texas
  251. Galveston, Texas
  252. Georgetown, Texas
  253. Georgetown, Texas
  254. Georgetown, Texas
  255. Georgetown, Texas
  256. Grapevine, Texas
  257. Houston, Texas
  258. Houston, Texas
  259. Houston, Texas
  260. Houston, Texas
  261. Houston, Texas
  262. Houston, Texas
  263. Houston, Texas
  264. Houston, Texas
  265. Houston, Texas
  266. Houston, Texas
  267. Houston, Texas
  268. Lampasas, Texas
  269. Lampasas, Texas
  270. League City, Texas
  271. Longview, Texas
  272. Longview, Texas
  273. Longview, Texas
  274. Longview, Texas
  275. McAllen, Texas
  276. Plano, Texas
  277. San Antonio, Texas
  278. San Antonio, Texas
  279. Tomball, Texas
  280. Weatherford, Texas
  281. Salt Lake City, Utah
  282. Salt Lake City, Utah
  283. Salt Lake City, Utah
  284. Salt Lake City, Utah
  285. Salt Lake City, Utah
  286. Salt Lake City, Utah
  287. Salt Lake City, Utah
  288. Salt Lake City, Utah
  289. Norfolk, Virginia
  290. Norfolk, Virginia
  291. Richmond, Virginia
  292. Richmond, Virginia
  293. Richmond, Virginia
  294. Richmond, Virginia
  295. Richmond, Virginia
  296. Richmond, Virginia
  297. Richmond, Virginia
  298. Virginia Beach, Virginia
  299. Seattle, Washington
  300. Seattle, Washington
  301. Seattle, Washington
  302. Seattle, Washington
  303. Seattle, Washington
  304. Seattle, Washington
  305. Seattle, Washington
  306. Shoreline, Washington
  307. Tacoma, Washington
  308. Tacoma, Washington
  309. Tacoma, Washington
  310. Tacoma, Washington
  311. Tacoma, Washington
  312. Huntington, West Virginia
  313. Huntington, West Virginia
  314. Huntington, West Virginia
  315. Huntington, West Virginia
  316. Marshfield, Wisconsin
  317. Marshfield, Wisconsin
  318. Rosario, Santa FE
  319. San Miguel de Tucuman, Tucuman
  320. San Miguel de Tucuman, Tucuman
  321. Buenos Aires,
  322. Caba,
  323. Caba,
  324. Salta,
  325. North Adelaide, South Australia
  326. Clayton, Victoria
  327. Geelong, Victoria
  328. Porto Alegre, RS
  329. Porto Alegre, RS
  330. Sorocaba, SP
  331. Halifax, Nova Scotia
  332. Montreal, Quebec
  333. Quebec,
  334. Osorno, Región DE LOS Lagos
  335. Santiago, Región Metropolitana
  336. Santiago, Región Metropolitana
  337. Santiago, Región Metropolitana
  338. Santiago, Región Metropolitana
  339. Santiago, Región Metropolitana
  340. Santiago, Región Metropolitana
  341. Santiago, Región Metropolitana
  342. Aarhus N,
  343. Hillerod,
  344. Hvidovre,
  345. Odense C,
  346. Helsinki,
  347. Kokkola,
  348. Oulu,
  349. Pori,
  350. Seinajoki,
  351. Tampere,
  352. Turku,
  353. Fajara, KMC,
  354. Amagasaki, Hyōgo
  355. Fujisawa, Kanagawa
  356. Kyoto-shi, Kyoto
  357. Kuwana-shi, MIE
  358. Sendai-city, Miyagi
  359. Beppu, Oita
  360. Nakagami-gun, Okinawa
  361. Habikino, Osaka
  362. Meguro-ku, Tokyo
  363. Saitama,
  364. Shizuoka,
  365. Hoofddorp,
  366. Utrecht,
  367. Utrecht,
  368. Auckland,
  369. Auckland,
  370. Christchurch,
  371. Christchurch,
  372. Wellington,
  373. Bloemfontein, FREE State
  374. Hillbrow, Johannesburg, Gauteng
  375. Johannesburg, Gauteng
  376. Pretoria, Gauteng
  377. Soshanguve, Gauteng
  378. Soweto, Gauteng
  379. Thabazimbi, Limpopo
  380. Khayelitsha, Western CAPE
  381. Parow Valley, Western CAPE
  382. Cape Town,
  383. Worcester,
  384. Santiago de Compostela, A Coruna
  385. Antequera, Malaga
  386. Madrid,
  387. Madrid,
  388. Mostoles,
  389. Valencia,
  390. Hsinchu City,
  391. Kaohsiung,
  392. Taipei City,
  393. Taipei,
  394. Taoyuan,
Female
11 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA Study to Evaluate the Safety and Immunogenicity of an Adjuvanted RSV Vaccine in Healthy Older Adults
NCT03572062
  1. South Brisbane, Queensland
  2. South Brisbane, Queensland
  3. Geelong, Victoria
  4. Fountain Hills, Arizona
  5. San Diego, California
  6. Coral Gables, Florida
  7. South Miami, Florida
  8. Peoria, Illinois
  9. Fremont, Nebraska
  10. Omaha, Nebraska
  11. Omaha, Nebraska
  12. Rochester, New York
  13. Rochester, New York
  14. South Jordan, Utah
  15. Adamstown, New South Wales
  16. Maroubra, New South Wales
  17. Merewether, New South Wales
  18. Sydney, New South Wales
  19. Sydney, New South Wales
  20. Westmead, New South Wales
  21. Westmead, New South Wales
  22. Sherwood, Queensland
  23. Box Hill, Victoria
  24. Box Hill, Victoria
  25. Camberwell, Victoria
  26. Camberwell, Victoria
  27. Clayton, Victoria
  28. Clayton, Victoria
  29. Geelong, Victoria
  30. Ivanhoe, Victoria
  31. Murdoch, Western Australia
  32. Murdoch, Western Australia
  33. Nedlands, Western Australia
  34. Nedlands, Western Australia
ALL GENDERS
65 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN
NCT04032093
  1. Santiago, Region Metropolitana
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. Birmingham, Alabama
  5. Cullman, Alabama
  6. Cullman, Alabama
  7. Cullman, Alabama
  8. Phoenix, Arizona
  9. Tucson, Arizona
  10. Tucson, Arizona
  11. Chowchilla, California
  12. Huntington Park, California
  13. Huntington Park, California
  14. Los Angeles, California
  15. Los Angeles, California
  16. Madera, California
  17. Madera, California
  18. Madera, California
  19. Madera, California
  20. Aurora, Colorado
  21. Aurora, Colorado
  22. Aurora, Colorado
  23. Aurora, Colorado
  24. Aurora, Colorado
  25. Aurora, Colorado
  26. Aurora, Colorado
  27. Atlanta, Georgia
  28. Atlanta, Georgia
  29. Blackfoot, Idaho
  30. Blackfoot, Idaho
  31. Blackfoot, Idaho
  32. Idaho Falls, Idaho
  33. Idaho Falls, Idaho
  34. Idaho Falls, Idaho
  35. Idaho Falls, Idaho
  36. Idaho Falls, Idaho
  37. Idaho Falls, Idaho
  38. Nampa, Idaho
  39. Nampa, Idaho
  40. Nampa, Idaho
  41. Nampa, Idaho
  42. Pocatello, Idaho
  43. Pocatello, Idaho
  44. Ankeny, Iowa
  45. West Des Moines, Iowa
  46. West Des Moines, Iowa
  47. El Dorado, Kansas
  48. Hutchinson, Kansas
  49. Alexandria, Louisiana
  50. Gretna, Louisiana
  51. Marrero, Louisiana
  52. Metairie, Louisiana
  53. Metairie, Louisiana
  54. New Orleans, Louisiana
  55. New Orleans, Louisiana
  56. Boston, Massachusetts
  57. Blaine, Minnesota
  58. Coon Rapids, Minnesota
  59. Coon Rapids, Minnesota
  60. Coon Rapids, Minnesota
  61. Coon Rapids, Minnesota
  62. Minneapolis, Minnesota
  63. Biloxi, Mississippi
  64. Gulfport, Mississippi
  65. Gulfport, Mississippi
  66. Gulfport, Mississippi
  67. Saint Louis, Missouri
  68. Saint Louis, Missouri
  69. Saint Louis, Missouri
  70. Missoula, Montana
  71. Missoula, Montana
  72. Lincoln, Nebraska
  73. Lincoln, Nebraska
  74. Lincoln, Nebraska
  75. Norfolk, Nebraska
  76. Henderson, Nevada
  77. Las Vegas, Nevada
  78. Albuquerque, New Mexico
  79. Albuquerque, New Mexico
  80. Albuquerque, New Mexico
  81. Binghamton, New York
  82. Endwell, New York
  83. Hempstead, New York
  84. Johnson City, New York
  85. Johnson City, New York
  86. Mineola, New York
  87. Mineola, New York
  88. Mineola, New York
  89. Mineola, New York
  90. Rochester, New York
  91. Rochester, New York
  92. Durham, North Carolina
  93. Durham, North Carolina
  94. Durham, North Carolina
  95. Durham, North Carolina
  96. Dayton, Ohio
  97. Dayton, Ohio
  98. Englewood, Ohio
  99. Kettering, Ohio
  100. Summerville, South Carolina
  101. Summerville, South Carolina
  102. Summerville, South Carolina
  103. Beaumont, Texas
  104. Beaumont, Texas
  105. Beaumont, Texas
  106. Beaumont, Texas
  107. Fort Worth, Texas
  108. Fort Worth, Texas
  109. Galveston, Texas
  110. Georgetown, Texas
  111. Georgetown, Texas
  112. Georgetown, Texas
  113. Georgetown, Texas
  114. Houston, Texas
  115. Houston, Texas
  116. Houston, Texas
  117. Houston, Texas
  118. Houston, Texas
  119. Houston, Texas
  120. Lampasas, Texas
  121. Lampasas, Texas
  122. Longview, Texas
  123. Longview, Texas
  124. Longview, Texas
  125. McAllen, Texas
  126. Pharr, Texas
  127. Plano, Texas
  128. Plano, Texas
  129. Round Rock, Texas
  130. Tomball, Texas
  131. Murray, Utah
  132. Salt Lake City, Utah
  133. Salt Lake City, Utah
  134. Salt Lake City, Utah
  135. Salt Lake City, Utah
  136. Salt Lake City, Utah
  137. Salt Lake City, Utah
  138. Richmond, Virginia
  139. Richmond, Virginia
  140. Huntington, West Virginia
  141. Huntington, West Virginia
  142. Huntington, West Virginia
  143. Huntington, West Virginia
  144. San Miguel de Tucuman, Tucuman
  145. San Miguel de Tucuman, Tucuman
  146. Cordoba,
  147. Salta,
  148. San Miguel de Tucuman,
  149. Santiago, Region Metropolitana
  150. Osorno, Región DE LOS Lagos
  151. Santiago, Región Metropolitana
  152. Santiago, Región Metropolitana
  153. Santiago, Región Metropolitana
  154. Santiago, Región Metropolitana
  155. Santiago, RM
  156. Soweto, Gauteng
  157. Soweto, Gauteng
Female
18 Years+
years
MULTIPLE SITES
Respiratory Tract InfectionA STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS
NCT04071158
  1. Stockbridge, Georgia
  2. Honolulu, Hawaii
  3. Wichita, Kansas
  4. Saint Louis, Missouri
  5. Omaha, Nebraska
  6. Oklahoma City, Oklahoma
  7. Warwick, Rhode Island
  8. Dakota Dunes, South Dakota
  9. Austin, Texas
  10. Fort Worth, Texas
  11. Houston, Texas
  12. San Antonio, Texas
  13. San Antonio, Texas
  14. Tomball, Texas
  15. Tomball, Texas
  16. Salt Lake City, Utah
  17. Salt Lake City, Utah
  18. South Jordan, Utah
Female
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS
Official Title  ICMJE A PHASE 2b, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE WHEN ADMINISTERED CONCOMITANTLY WITH TETANUS, DIPHTHERIA, AND ACELLULAR PERTUSSIS VACCINE (TDAP) IN HEALTHY NONPREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE
Brief Summary This phase 2b study will evaluate safety, tolerability, and immunogenicity of an RSV vaccine when given together with Tdap in approximately 710 healthy nonpregnant women 18 through 49 years of age. This study will evaluate non-inferiority of RSV vaccine when given with Tdap and vice-versa.
Detailed Description

This Phase 2b study will evaluate safety, tolerability, and immunogenicity of an RSV vaccine when given together with Tdap in approximately 710 healthy nonpregnant women 18 through 49 years of age.

The participants will be equally split into 5 treatment groups: One of a possible two dose levels of RSV vaccine (the higher dose level will be formulated with an aluminum hydroxide adjuvant) with either the Tdap or Placebo, or a Tdap and placebo combination.

This study will evaluate non-inferiority of the Tdap when co-administered with RSV vaccine candidate and vice-versa by measuring participants' immune response through appropriate antibody and component levels 1 month after vaccination.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description:
This is an observer-blinded study. Study staff dispensing and administering the vaccine will be unblinded, but the participant and all other study personnel, including the principal investigator, will be blinded.
Primary Purpose: Prevention
Condition  ICMJE Respiratory Tract Infection
Intervention  ICMJE
  • Biological: RSV Vaccine
    RSV vaccine
  • Biological: Tdap
    Tetanus, Diphtheria, and Acellular Pertussis Vaccine
  • Biological: Placebo
    Normal saline solution for injection (0.9% sodium chloride injection)
Study Arms  ICMJE
  • Experimental: Lower RSV vaccine dose and Tdap
    Lower RSV vaccine dose and Tdap
    Interventions:
    • Biological: RSV Vaccine
    • Biological: Tdap
  • Experimental: Lower RSV vaccine dose and Placebo
    Lower RSV vaccine dose and Placebo
    Interventions:
    • Biological: RSV Vaccine
    • Biological: Placebo
  • Experimental: Higher RSV vaccine dose with Aluminum Hydroxide and Tdap
    Higher RSV vaccine dose with Aluminum Hydroxide and Tdap
    Interventions:
    • Biological: RSV Vaccine
    • Biological: Tdap
  • Experimental: Higher RSV vaccine dose with Aluminum Hydroxide and Placebo
    Higher RSV vaccine dose with Aluminum Hydroxide and Placebo
    Interventions:
    • Biological: RSV Vaccine
    • Biological: Placebo
  • Placebo Comparator: Placebo and Tdap
    Normal saline solution for injection (0.9% sodium chloride injection) and Tdap
    Interventions:
    • Biological: Tdap
    • Biological: Placebo
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: July 8, 2020)
713
Original Estimated Enrollment  ICMJE
 (submitted: August 26, 2019)
680
Actual Study Completion Date  ICMJE December 11, 2019
Actual Primary Completion Date December 11, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Healthy women ?18 and ?49 years of age who are of childbearing potential or not of childbearing potential. (Healthy participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, can be included.)
  • Willing and able to comply with all scheduled visits, treatment plan, lifestyle considerations, and other study procedures.
  • Expected to be available for the duration of the study and can be contacted by telephone during study participation.
  • Body mass index (BMI) of <40 kg/m2 at the time of the consent.
  • Capable of giving signed informed consent as which includes compliance with the requirements and restrictions listed within.

Exclusion Criteria:

  • Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
  • Known infection with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis B virus (HBV).
  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the vaccines being administered in the study.
  • History of latex allergy.
  • Immunocompromised participants with known or suspected immunodeficiency, as determined by history, laboratory tests, and/or physical examination.
  • Any contraindication to Tdap (including encephalopathies).
  • History of autoimmune disease or an active autoimmune disease requiring therapeutic intervention, including but not limited to systemic or cutaneous lupus erythematosus, autoimmune arthritis/rheumatoid arthritis, Guillain-Barré syndrome, multiple sclerosis, Sjögren's syndrome, idiopathic thrombocytopenia purpura, glomerulonephritis, autoimmune thyroiditis, giant cell arteritis (temporal arteritis), psoriasis, and insulin dependent diabetes mellitus (type 1).
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Women who are pregnant or breastfeeding.
  • Previous vaccination with any licensed or investigational RSV vaccine, or planned receipt of nonstudy RSV vaccine throughout the study.
  • Treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease, or planned receipt throughout the study. If systemic corticosteroids have been administered short term (<14 days) for treatment of an acute illness, participants should not be enrolled into the study until corticosteroid therapy has been discontinued for at least 28 days before investigational product administration. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
  • Receipt of blood/plasma products or immunoglobulin within 60 days before investigational product administration or planned receipt throughout the study.
  • Current alcohol abuse, marijuana abuse, or illicit drug use.
  • Vaccination within 5 years with DTaP or tetanus and diphtheria toxoids adsorbed (Td) vaccine before investigational product administration.
  • Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or Pfizer employees, including their family members, directly involved in the conduct of the study.
  • Current febrile illness (oral temperature ?38.0C [?100.4F]) or other acute illness within 48 hours before investigational product administration.
  • Receipt of any inactivated vaccine within 14 days and any live vaccine within 28 days before or anticipated receipt of any vaccine within the 14 days after investigational product administration.
  • Receipt of short-term (<14 days) systemic corticosteroids. Investigational product administration should be delayed until systemic corticosteroid use has been discontinued for at least 28 days. Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids do not require temporary delay of investigational product administration.
Sex/Gender  ICMJE
Sexes Eligible for Study:Female
Gender Based Eligibility:Yes
Gender Eligibility Description:Healthy, non-pregnant women 18 to 49 years of age, who are of childbearing potential or not of childbearing potential.
Ages  ICMJE 18 Years to 49 Years   (Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04071158
Other Study ID Numbers  ICMJE C3671004
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d….
URL:https://www.pfizer.com/science/clinical_trials/trial_data_and_results/d…
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date January 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP